Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2007, Article ID 58901, 9 pages
http://dx.doi.org/10.1155/2007/58901
Research Article

Administration of PDE4 Inhibitors Suppressed the Pannus-Like Inflammation by Inhibition of Cytokine Production by Macrophages and Synovial Fibroblast Proliferation

Pharmacological Research Laboratories, Pharmaceutical Research Center, Kyowa Hakko Kogyo Co., Ltd., 1188 Shimotogari, Nagaizumi-Cho, Sunto-Gun, Shizuoka-Ken 411-8731, Japan

Received 18 May 2007; Revised 10 August 2007; Accepted 3 September 2007

Copyright © 2007 Katsuya Kobayashi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. E. Trentham, A. S. Townes, and A. H. Kang, “Autoimmunity to type II collagen: an experimental model of arthritis,” Journal of Experimental Medicine, vol. 146, no. 3, pp. 857–868, 1977. View at Publisher · View at Google Scholar
  2. K. D. Rainsford, “Adjuvant polyarthritis in rats: is this a satisfactory model for screening anti-arthritic drugs?,” Agents & Actions, vol. 12, no. 4, pp. 452–458, 1982. View at Publisher · View at Google Scholar
  3. K. Magari, S. Miyata, Y. Ohkubo, and S. Mutoh, “Inflammatory cytokine levels in paw tissues during development of rat collagen-induced arthritis: effect of FK506, an inhibitor of T cell activation,” Inflammation Research, vol. 53, no. 9, pp. 469–474, 2004. View at Publisher · View at Google Scholar · View at PubMed
  4. G. Engelhardt, D. Homma, K. Schlegel, R. Utzmann, and C. Schnitzler, “Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance,” Inflammation Research, vol. 44, no. 10, pp. 423–433, 1995. View at Publisher · View at Google Scholar
  5. C. Vingsbo, P. Sahlstrand, J. G. Brun, R. Jonsson, T. Saxne, and R. Holmdahl, “Pristane-induced arthritis in rats: a new model for rheumatoid arthritis with a chronic disease course influenced by both major histocompatibility complex and non-major histocompatibility complex genes,” American Journal of Pathology, vol. 149, no. 5, pp. 1675–1683, 1996.
  6. C. J. Dunn, A. J. Gibbons, and S. K. Miller, “Development of a delayed-type hypersensitivity granuloma model in the mouse for the study of chronic immune-mediated inflammatory disease,” Agents & Actions, vol. 27, no. 3-4, pp. 365–368, 1989. View at Publisher · View at Google Scholar
  7. C. J. Dunn, L. A. Galinet, A. J. Gibbons, and S. K. Shields, “Murine delayed-type hypersensitivity granuloma: an improved model for the identification and evaluation of different classes of anti-arthritic drugs,” International Journal of Immunopharmacology, vol. 12, no. 8, pp. 899–904, 1990. View at Publisher · View at Google Scholar
  8. B. Särnstrand, A.-H. Jansson, G. Matuseviciene, A. Scheynius, S. Pierrou, and H. Bergstrand, “N,N-diacetyl-L-cystine—the disulfide dimer of N-acetylcysteine—is a potent modulator of contact sensitivity/delayed type hypersensitivity reactions in rodents,” Journal of Pharmacology and Experimental Therapeutics, vol. 288, no. 3, pp. 1174–1184, 1999.
  9. W. Bäumer, J. Hoppmann, C. Rundfeldt, and M. Kietzmann, “Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis,” Inflammation & Allergy - Drug Targets, vol. 6, no. 1, pp. 17–26, 2007.
  10. L. Sekut, D. Yarnall, and S. A. Stimpson et al., “Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation,” Clinical & Experimental Immunology, vol. 100, no. 1, pp. 126–132, 1995.
  11. J. N. Francischi, C. M. Yokoro, S. Poole, W. L. Tafuri, F. Q. Cunha, and M. M. Teixeira, “Anti-inflammatory and analgesic effects of the phosphodiesterase 4 inhibitor rolipram in a rat model of arthritis,” European Journal of Pharmacology, vol. 399, no. 2-3, pp. 243–249, 2000. View at Publisher · View at Google Scholar
  12. L. Wollin, D. S. Bundschuh, A. Wohlsen, D. Marx, and R. Beume, “Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors,” Pulmonary Pharmacology & Therapeutics, vol. 19, no. 5, pp. 343–352, 2006. View at Publisher · View at Google Scholar · View at PubMed
  13. A. Kanehiro, T. Ikemura, and M. J. Mäkelä et al., “Inhibition of phosphodiesterase 4 attenuates airway hyperresponsiveness and airway inflammation in a model of secondary allergen challenge,” American Journal of Respiratory and Critical Care Medicine, vol. 163, no. 1, pp. 173–184, 2001.
  14. F. J. Johnson, L. J. Reynolds, and T. J. Toward, “Elastolytic activity and alveolar epithelial type-1 cell damage after chronic LPS inhalation: effects of dexamethasone and rolipram,” Toxicology and Applied Pharmacology, vol. 207, no. 3, pp. 257–265, 2005. View at Publisher · View at Google Scholar · View at PubMed
  15. S. E. Ross, R. O. Williams, and L. J. Mason et al., “Suppression of TNF-α expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram,” Journal of Immunology, vol. 159, no. 12, pp. 6253–6259, 1997.
  16. Z. Huang and J. A. Mancini, “Phosphodiesterase 4 inhibitors for the treatment of asthma and COPD,” Current Medicinal Chemistry, vol. 13, no. 27, pp. 3253–3562, 2006. View at Publisher · View at Google Scholar
  17. N. Cooper, M. M. Teixeira, and J. Warneck et al., “A comparison of the inhibitory activity of PDE4 inhibitors on leukocyte PDE4 activity in vitro and eosinophil trafficking in vivo,” British Journal of Pharmacology, vol. 126, no. 8, pp. 1863–1871, 1999. View at Publisher · View at Google Scholar · View at PubMed
  18. P. L. van Lent, K. Nabbe, and A. B. Blom et al., “Role of activatory FcγRI and FcγRIII and inhibitory FcγRII in inflammation and cartilage destruction during experimental antigen-induced arthritis,” American Journal of Pathology, vol. 159, no. 6, pp. 2309–2320, 2001.
  19. C. Romay, N. Ledón, and R. González, “Further studies on anti-inflammatory activity of phycocyanin in some animal models of inflammation,” Inflammation Research, vol. 47, no. 8, pp. 334–338, 1998. View at Publisher · View at Google Scholar
  20. C. Jakubzick, E. S. Choi, and B. H. Joshi et al., “Therapeutic attenuation of pulmonary fibrosis via targeting of IL-4- and IL-13-responsive cells,” Journal of Immunology, vol. 171, no. 5, pp. 2684–2693, 2003.
  21. F. A. Meyer, I. Yaron, V. Mashiah, and M. Yaron, “Methotrexate inhibits proliferation but not interleukin 1 stimulated secretory activities of cultured human synovial fibroblasts,” Journal of Rheumatology, vol. 20, no. 2, pp. 238–242, 1993.
  22. N. J. Olsen and L. M. Murray, “Antiproliferative effects of methotrexate on peripheral blood mononuclear cells,” Arthritis & Rheumatism, vol. 32, no. 4, pp. 378–385, 1989. View at Publisher · View at Google Scholar
  23. G. S. Firestein, “Evolving concepts of rheumatoid arthritis,” Nature, vol. 423, no. 6937, pp. 356–361, 2003. View at Publisher · View at Google Scholar · View at PubMed
  24. A. Bucht, P. Larsson, and L. Weisbrot et al., “Expression of interferon-gamma (IFN-γ), IL-10, IL-12 and transforming growth factor-beta (TGF-β) mRNA in synovial fluid cells from patients in the early and late phases of rheumatoid arthritis (RA),” Clinical & Experimental Immunology, vol. 103, no. 3, pp. 357–367, 1996.
  25. Y. Morita, M. Yamamura, and K. Nishida et al., “Expression of interleukin-12 in synovial tissue from patients with rheumatoid arthritis,” Arthritis & Rheumatism, vol. 41, no. 2, pp. 306–314, 1998. View at Publisher · View at Google Scholar
  26. F. Puppo, G. Murdaca, M. Ghio, and F. Indiveri, “Emerging biologic drugs for the treatment of rheumatoid arthritis,” Autoimmunity Reviews, vol. 4, no. 8, pp. 537–541, 2005. View at Publisher · View at Google Scholar · View at PubMed
  27. E. H. Choy, D. A. Isenberg, and T. Garrood et al., “Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial,” Arthritis & Rheumatism, vol. 46, no. 12, pp. 3143–3150, 2002. View at Publisher · View at Google Scholar · View at PubMed
  28. N. Nishimoto, K. Yoshizaki, and N. Miyasaka et al., “Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial,” Arthritis & Rheumatism, vol. 50, no. 6, pp. 1761–1769, 2004. View at Publisher · View at Google Scholar · View at PubMed
  29. V. Kouskoff, A.-S. Korganow, V. Duchatelle, C. Degott, C. Benoist, and D. Mathis, “Organ-specific disease provoked by systemic autoimmunity,” Cell, vol. 87, no. 5, pp. 811–822, 1996. View at Publisher · View at Google Scholar
  30. M. Feldmann, F. M. Brennan, and R. N. Maini, “Role of cytokines in rheumatoid arthritis,” Annual Review of Immunology, vol. 14, pp. 397–440, 1996. View at Publisher · View at Google Scholar · View at PubMed
  31. D. E. Griswold, E. F. Webb, and A. M. Badger et al., “SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor α and interleukin-4 production in vivo,” Journal of Pharmacology and Experimental Therapeutics, vol. 287, no. 2, pp. 705–711, 1998.
  32. H.-S. Cha, T. J. Kim, and J.-Y. Kim et al., “Autoantibodies to glucose-6-phosphate isomerase are elevated in the synovial fluid of rheumatoid arthritis patients,” Scandinavian Journal of Rheumatology, vol. 33, no. 3, pp. 179–184, 2004. View at Publisher · View at Google Scholar
  33. M. Schaller, W. Stohl, V. Benoit, S.-M. Tan, L. Johansen, and H. J. Ditzel, “Patients with inflammatory arthritic diseases harbor elevated serum and synovial fluid levels of free and immune-complexed glucose-6-phosphate isomerase (G6PI),” Biochemical and Biophysical Research Communications, vol. 349, no. 2, pp. 838–845, 2006. View at Publisher · View at Google Scholar · View at PubMed
  34. K. Yamaki, X. Li, and H. Uchida et al., “Effects of the phosphodiesterase IV inhibitor rolipram on Th1 and Th2 immune responses in mice,” Journal of Pharmacy and Pharmacology, vol. 56, no. 7, pp. 877–882, 2004. View at Publisher · View at Google Scholar · View at PubMed
  35. K. Yamaki, X. Li, and M. A. Hossain et al., “Difference in preventive effects between the phosphodiesterase IV inhibitor rolipram and anti-arthritic drugs on antigen-induced arthritis in mice,” Immunological Investigations, vol. 36, no. 2, pp. 131–145, 2007. View at Publisher · View at Google Scholar · View at PubMed
  36. A. Hatzelmann and C. Schudt, “Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro,” Journal of Pharmacology and Experimental Therapeutics, vol. 297, no. 1, pp. 267–279, 2001.
  37. D. Claveau, S. L. Chen, and S. O'Keefe et al., “Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-{2-(3,4-bisdifluromethoxyphenyl)-2-{4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl}-3-methylpyridine-1-oxide], a Potent and Selective Phosphodiesterase 4 Inhibitor,” Journal of Pharmacology and Experimental Therapeutics, vol. 310, no. 2, pp. 752–760, 2004. View at Publisher · View at Google Scholar · View at PubMed
  38. H. C. Heystek, A.-C. Thierry, P. Soulard, and C. Moulon, “Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity,” International Immunology, vol. 15, no. 7, pp. 827–835, 2003. View at Publisher · View at Google Scholar
  39. I. B. McInnes and G. Schett, “Cytokines in the pathogenesis of rheumatoid arthritis,” Nature Reviews Immunology, vol. 7, no. 6, pp. 429–442, 2007. View at Publisher · View at Google Scholar · View at PubMed